A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01647711
• Other study ID #: 1200.121
• Status: Completed
• Phase: Phase 1
• First received: July 16, 2012
• Last updated: December 21, 2015
• Start date: July 2012
• Est. completion date: September 2015

Study information

• Verified date: December 2015
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This trial is divided into Part A and Part B. The primary objective of Part A is to establish the Maximal Tolerated Dose of intermittent high dose afatinib. The primary objective of Part B is to assess the response rate of patients with non-small cell lung cancer with EGFR T790M mutations to a dose of intermittent afatinib established in Part A.

The secondary objective is to explore tumor response and tumor-derived biological markers of response to afatinib, as well as pharmacokinetic parameters of afatinib.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: September 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

Part A only:

1. Patients with histologically confirmed advanced solid tumours that are metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. Patients who refuse standard therapy are also eligible.

Part B only:

2. Pathologically confirmed diagnosis of Stage IV (M1a or b) non-small cell lung cancer

3. Documented Epidermal Growth Factor Receptor (EGFR) T790M mutation

4. Progression of disease on a reversible tyrosine kinase inhibitor within 30 days of starting study drug. Loss of exposure to prior EGFR TKI should not be >30 days; any procedural delay in confirmation of progression is to be discussed with the BI Clinical Monitor.

Parts A and B:

5. Evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

6. Age >/= to 18 years

7. Eastern Cooperative Group (ECOG) performance status 0-1

8. Adequate organ function

9. Recovered from any previous therapy-related toxicity to </= to Grade 1 at study entry (except for stable sensory neuropathy </= Grade 2 and alopecia)

10. Written informed consent

11. Ability to take oral medication

Exclusion criteria:

Parts A and B:

1. Chemotherapy, biological therapy, or investigational agents (except erlotinib or gefitinib) within 4 weeks prior to the start of study treatment

2. Hormonal treatment within 2 weeks prior to the start of study treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer is permitted)

3. Radiotherapy within two weeks prior to the start of study treatment (except palliative radiotherapy given for symptom control)

4. Less than 3 days from prior treatment with gefitinib or erlotinib. Patients with adverse events related to gefitinib or erlotinib must recover to Grade 1 or less to be eligible.

5. Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study

6. Known hypersensitivity to afatinib or the excipients of any of the trial drugs

7. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to starting study treatment

8. Women of childbearing potential and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended.

9. Female patients of childbearing potential who are nursing; are pregnant; are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study; and do not agree to submit to pregnancy testing required by this protocol

10. Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug

11. Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured

12. Required treatment with any of the prohibited medications listed in this protocol that cannot be stopped for the duration of trial participation

13. Known pre-existing Interstitial Lung Disease

14. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (for example, Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption) in the opinion of the investigator

15. Active hepatitis B infection (defined as the presence of Hepatitis B DNA), active hepatitis C infection (defined as the presence of Hepatitis C RNA) and/or known Human Immunodeficiency Virus carrier

16. Prior participation in a blinded afatinib clinical study, unless permission to unblind was granted in consultation with the Clinical Monitor of the blinded study

17. Meningeal carcinomatosis

18. Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued use of corticosteroids or have been on stable doses of corticosteroids for at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment

19. QTc interval > 0.47 seconds as measured during screening procedures

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung

Intervention

Drug:
• Dose escalation followed by treatment with MTD
Fixed 3+3 dose escalation; expansion of MTD cohort

Locations

Country	Name	City	State
United States	1200.121.01001 Boehringer Ingelheim Investigational Site	Aurora	Colorado
United States	1200.121.01002 Boehringer Ingelheim Investigational Site	Boston	Massachusetts
United States	1200.121.01004 Boehringer Ingelheim Investigational Site	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of Maximally Tolerated Dose (MTD) of intermittent high-dose afatinib		up to 36 months	No
Secondary	Objective response rate for patients with EGFR T790M mutations according to RECIST v1.1		up to 36 months	No
Secondary	Cmax of afatinib as determined on day 3 of course 1 for patients in Part A		up to 36 months	No
Secondary	Determination of dosage for expansion cohort in Part B		up to 36 months	No